Graft vascular disease: Immune response meets the vessel wall

Annual Review of Pathology: Mechanisms of Disease

Volumn 4, Issue , 2009, Pages 19-47

  Mitchell, Richard N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Rejection; Transplantation; Vasculopathy

Indexed keywords

ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; ASCORBIC ACID; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD20 ANTIBODY; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1 MONOCLONAL ANTIBODY; CYTOKINE; FRACTALKINE; FRACTALKINE MONOCLONAL ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON MONOCLONAL ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 4; OKT 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RANTES; RAPAMYCIN; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4 MONOCLONAL ANTIBODY;

ANTIGEN PRESENTATION; ATHEROSCLEROSIS; BLOOD VESSEL GRAFT; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIAC GRAFT REJECTION; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; DRUG ELUTING STENT; DYSLIPIDEMIA; GRAFT FAILURE; GRAFT VASCULAR DISEASE; HEART GRAFT; HOST CELL; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; ALLOTRANSPLANTATION; ANIMAL; ARTERY; CELL MOTION; DISEASE MODEL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HYPERPLASIA; IMMUNOLOGY; METABOLISM; ORGAN TRANSPLANTATION; PATHOLOGY; TRANSPLANTATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; CELL MOVEMENT; CYTOKINES; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; HYPERPLASIA; IMMUNITY, INNATE; MUSCLE, SMOOTH, VASCULAR; ORGAN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 66149100472     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.3.121806.151449     Document Type: Review

References (143)

1. Valantine H. 2004. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transpl. 23(Suppl. 5):S187-93 (Pubitemid 38496395)
2. Rahmani M, Cruz R, Granville DJ, McManus B. 2006. Allograft vasculopathy versus atherosclerosis. Circ. Res. 99:801-815
3. Libby P, Pober J. 2001. Chronic rejection. Immunity 14:387-397
4. McManus B, Horley K, Wilson J, Malcom G, Kendall T, et al. 1995. Prominence of coronary arterial wall lipids in human heart allografts: implications for pathogenesis of allograft arteriopathy. Am. J. Pathol. 147:293-308
5. Johnson D, Gao S, Schroeder J, DeCampli W, Billingham M. 1989. The spectrum of coronary artery pathologic findings in human cardiac allografts. J. Heart Transpl. 8:349-359 (Pubitemid 19247624)
6. Salomon R, Hughes C, Schoen F, Payne D, Pober J, et al. 1991. Human coronary transplantation- associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am. J. Pathol. 138:791-798
7. Furukawa Y, Libby P, Stinn J, Becker G, Mitchell R. 2002. Cold ischemia enhances cytokine/cell adhesion molecule expression and induces graft arterial disease in isografts, but does not accentuate alloimmune responses of nonimmunosuppressed hosts. Am. J. Pathol. 160:1077-1087
8. Dhaliwal A, Thohan V. 2006. Cardiac allograft vasculopathy: the Achilles heel of long-term survival after cardiac transplantation. Curr. Atheroscler. Rep. 8:119-130
9. Costanzo M, Naftel D, Pritzker M, Heilman J, Boehmer J, et al. 1998. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J. Heart Lung Transpl. 17:744-753 (Pubitemid 28396983)
10. Libby P, Salomon R, Payne D, Schoen F, Pober J. 1989. Functions of vascular wall cells related to the development of transplant-associated coronary arteriosclerosis. Transpl. Proc. 21:3677-3684 (Pubitemid 20297514)
11. Owens G. 1995. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75:487-517
12. Nagai R, Suzuki T, Aizawa K, Miyamoto S, Amaki T, et al. 2001. Phenotypic modulation of vascular smooth muscle cells: dissection of transcriptional regulatory mechanisms. Ann. N.Y. Acad. Sci. 947:56-66 (Pubitemid 34059903)
13. Shah R, Mitchell R. 2005. The role of stem cells in the response to myocardial and vascular wall injury. Cardiovasc. Pathol. 14:225-231 (Pubitemid 41317268)
14. Tuzcu E, Kapadia S, Sachar R, Ziada K, Crowe T, et al. 2005. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J. Am. Coll. Cardiol. 45:1538-1542 (Pubitemid 40615631)
15. Fang J, Rocco T, Jarcho J, Ganz P, Mudge J. 1998. Noninvasive assessment of transplant-associated arterial sclerosis. Am. Heart J. 135:980-987 (Pubitemid 28316993)
16. Davis S, Yeung A, Meredith I, Charbonneau F, Ganz P, et al. 1996. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 93:457-462 (Pubitemid 26043604)
17. Hollenberg S, Klein L, Parrillo J, Scherer M, Burns D, et al. 2004. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J. Heart Lung Transpl. 23:265-271 (Pubitemid 38333082)
18. Fearon W, Hirohata A, Nakamura M, Luikart H, Lee D, et al. 2006. Discordant changes in epicardial and microvascular coronary physiology after cardiac transplantation: Physiologic Investigation forTransplant Arteriopathy II (PITA II) study. J. Heart Lung Transpl. 25:765-771 (Pubitemid 43963368)
19. Tuzcu E, Hobbs R, Rincon G, Bott-Silverman C, Franco AD, et al. 1995. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation 91:1706-1713
20. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, et al. 2005. Cardiac allograft vasculopathy: a review. Can. J. Surg. 48:319-327
21. Hauptman P, Nakagawa T, Tanaka H, Libby P. 1995. Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease? J. Heart Lung Transpl. 14:S173-80 (Pubitemid 26011260)
22. Kuo E, Bharat A, Shih J, Street T, Norris J, et al. 2006. Role of airway epithelial injury in murine orthotopic tracheal allograft rejection. Ann. Thorac. Surg. 82:1226-1233 (Pubitemid 44402353)
23. George J, Pinderski L, Litovsky S, Kirklin J. 2005. Of mice and men: mouse models and the molecular mechanisms of post-transplant coronary artery disease. J. Heart Lung Transpl. 24:2003-2014 (Pubitemid 41814717)
24. Shimizu K, Mitchell R. 2006. Murine models of allograft arteriopathy: heterotopic heart transplantation and aortic interposition grafts. In A Handbook of Mouse Models for Cardiovascular Diseases, ed. Q Xu, pp. 173-92.West Sussex, Eng.:Wiley
25. Soleimani B, Shi V. 2006. Experimental models of graft arteriosclerosis. Methods Mol. Biol. 333:401-424
26. Russell P, Chase C, Win H, Colvin R. 1994. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am. J. Pathol. 144:260-274 (Pubitemid 24165947)
27. Nagano H, Mitchell R, Taylor M, Hasegawa S, Tilney N, et al. 1997. Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J. Clin. Invest. 100:550-557 (Pubitemid 27340501)
28. Fey T, Krause R, Hsieh G, Andrews J, Bretheim P, et al. 1998. Improved methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats. J. Pharmacol. Toxicol. Methods 39:9-17 (Pubitemid 28221554)
29. Tomita Y, Zhang Q, Uchida T, Yoshikawa M, Shimizu I, et al. 1997. A technique of cervical aortic graft transplantation in mice. J. Heart Lung Transpl. 20:699-702
30. Arai S, Teramoto S, Senoo Y. 1992. The impact of FK506 on graft coronary disease of rat cardiac allograft-a comparison with cyclosporine. J. Heart Lung Transpl. 11:757-762
31. Taqueti V, Mitchell R, Lichtman A. 2006. Protecting the pump: controlling myocardial inflammatory responses. Annu. Rev. Physiol. 68:67-95
32. Tellides G, Tereb D, Kirkiles-Smith N, Kim R, Wilson J, et al. 2000. Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature 403:207-211 (Pubitemid 30050965)
33. Hasegawa S, Becker G, Nagano H, Libby P, Mitchell R. 1998. Pattern of graft- and host-specific MHC class II expression in long-term murine cardiac allografts. Origin of inflammatory and vascular wall cells. Am. J. Pathol. 153:1-11 (Pubitemid 28317509)
34. Plissonier D, Nochy D, Poncet P, Mandet C, Hinglais N, et al. 1995. Sequential immunological targeting of chronic experimental arterial allograft. Transplantation 60:414-424
35. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, et al. 2001. Host bone-marrow cells are a source of donor intimal smooth muscle-like cells in murine aortic transplant arteriopathy. Nat. Med. 7:738-741 (Pubitemid 32588032)
36. Tellides G, Pober J. 2007. Interferon-γ axis in graft arteriosclerosis. Circ. Res. 100:622-632
37. Halloran P, Miller L, Urmson J, Ramassar V, Zhu L, et al. 2001. IFN-γ alters the pathology of graft rejection: protection from early necrosis. J. Immunol. 166:7072-7081 (Pubitemid 32525576)
38. Russell P, Chase C, Winn H, Colvin R. 1994. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J. Immunol. 152:5135-5141 (Pubitemid 24139110)
39. Furukawa Y, Cole S, Shah R, Fukumoto Y, Libby P, et al. 2004.Wild-type but not interferon-γ-deficient T cells induce graft arterial disease in the absence of B cells. Cardiovasc. Res. 63:347-356 (Pubitemid 38900849)
40. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell R. 2001. Cerivastatin has immunomodulatory effects on donor endothelial cells and host inflammatory cells and attenuates allograft arteriopathy. Circulation 104:II212-13
41. Kwak B, Mulhaupt F, Mach F. 2003. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun. Rev. 2:332-338 (Pubitemid 37211387)
42. Caforio A, Tona F, Fortina A, Angelini A, Piaserico S, et al. 2004. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am. J. Transpl. 4:962-970 (Pubitemid 38750168)
43. Gallucci S, Matzinger P. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13:114-119 (Pubitemid 32096970)
44. el-Sawy T, Fahmy N, Fairchild R. 2002. Chemokines: directing leukocyte infiltration into allografts. Curr. Opin. Immunol. 14:562-568
45. Kocher A, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, et al. 2003. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J. Heart Lung Transpl. 22:250-257 (Pubitemid 36299163)
46. Valantine H. 2004. The role of viruses in cardiac allograft vasculopathy. Am. J. Transpl. 4:169-177 (Pubitemid 38248518)
47. Streblow D, Kreklywich C, Andoh T, Moses A, Dumortier J, et al. 2008. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am. J. Transpl. 8:277-287
48. Michaels P, Espejo M, Kobashigawa J, Alejos J, Burch C, et al. 2003. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J. Heart Lung Transpl. 22:58-69 (Pubitemid 36071418)
49. Wehner J, Morrell C, Reynolds T, Rodriguez E, Baldwin W. 2007. Antibody and complement in transplant vasculopathy. Circ. Res. 100:191-203
50. Ross R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:115-126
51. Biedermann B, Pober J. 1999. Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL. J. Immunol. 162:7022-7030 (Pubitemid 29277669)
52. Koh K, Wang Y, Yi T, Shiao S, Lorber M, et al. 2004. T cell-mediated vascular dysfunction of human allografts results from IFN-γ dysregulation of NO synthase. J. Clin. Invest. 114:846-856 (Pubitemid 39578744)
53. Jiang S, Herrera O, Lechler R. 2004. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr. Opin. Immunol. 16:550-557 (Pubitemid 39165880)
54. Lee R, Yamada K, Houser S,Womer K, Maloney M, et al. 2001. Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transpl. Proc. 33:308-310 (Pubitemid 32237388)
55. Ensminger S, Spriewald B,Witzke O, Pajaro O, Yacoub M, et al. 2002. Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation 73:279-286 (Pubitemid 34112854)
56. Ardehali A, Fischbein M, Yun J, Irie Y, Fishbein M, et al. 2002. Indirect alloreactivity and chronic rejection. Transplantation 73:1805-1807
57. Hornick P, Mason P, Yacoub M, Rose M, Batchelor R, et al. 1998. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 97:1257-1263 (Pubitemid 28169177)
58. Hornick P, Mason P, Baker R, Hernandez-Fuentes M, Frasca L, et al. 2000. Significant frequencies of T cells with indirect antidonor specificity in heart graft recipients with chronic rejection. Circulation 101:2405-2410 (Pubitemid 30329132)
59. Nagano H, Libby P, Taylor M, Hasegawa S, Stinn J, et al. 1998. Coronary arteriosclerosis after T cell-mediated injury in transplanted mouse hearts. Role of interferon-γ. Am. J. Pathol. 152:1187-1197 (Pubitemid 28221872)
60. Tori M, Kitagawa-Sakakida S, Li Z, Izutani H, Horiguchi K, et al. 2000. Initial T cell activation required for transplant vasculopathy in retransplanted rat cardiac allografts. Transplantation 70:737-746
61. Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell R. 2000. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J. Immunol. 165:3506-3518 (Pubitemid 30728211)
62. Raisky O, Spriewald B, Morrison K, Ensminger S, Mohieddine T, et al. 2003. CD8(+) T cells induce graft vascular occlusion in a CD40 knockout donor/recipient combination. J. Heart Lung Transpl. 22:177-183 (Pubitemid 36173675)
63. Glysing-Jensen T, Raisanen-Sokolowski A, Sayegh M, Russell M. 1997. Chronic blockade of CD28-B7- mediated T cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation 64:1641-1645 (Pubitemid 28041693)
64. Furukawa Y, Mandelbrot D, Libby P, Sharpe A, Mitchell R. 2000. Association of B7-1 costimulation with the development of graft arterial disease: studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am. J. Pathol. 157:473-484 (Pubitemid 30626910)
65. Kim K, Denton M, Chandraker A, Knoflach A, Milord R, et al. 2001. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158:977-986 (Pubitemid 32221789)
66. Kosuge H, Suzuki J, Haraguchi G, Koga N, Maejima Y, et al. 2006. Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler. Thromb. Vasc. Biol. 26:2660-2665 (Pubitemid 44777279)
67. Hancock W, Buelow R, Sayegh M, Turka L. 1998. Antibody-induced transplant arteriosclerosis is prevented by graft expression of antioxidant and antiapoptotic genes. Nat. Med. 4:1392-1396 (Pubitemid 28553461)
68. Terasaki P, Ozawa M. 2004. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transpl. 4:438-443 (Pubitemid 38282302)
69. Thurman J, Holers V. 2006. The central role of the alternative complement pathway in human disease. J. Immunol. 176:1305-1310 (Pubitemid 43134269)
70. Yamakuchi M, Kirkiles-Smith N, Ferlito M, Cameron S, Bao C, et al. 2007. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc. Natl. Acad. Sci. USA 104:1301-1306 (Pubitemid 46183999)
71. Thaunat O, Louedec L, Dai J, Bellier F, Groyer E, et al. 2006. Direct and indirect effects of alloantibodies link neointimal and medial remodeling in graft arteriosclerosis. Arterioscler. Thromb. Vasc. Biol. 26:2359-2365 (Pubitemid 44465734)
72. Michaels P, Fishbein M, Colvin R. 2003. Humoral rejection of human organ transplants. Springer Semin. Immunopathol. 25:119-140 (Pubitemid 37134579)
73. Rossi D, Zlotnick A. 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18:217-242
74. Wang Y, Burns W, Tang P, Yi T, Schechner J, et al. 2004. Interferon-γ plays a nonredundant role in mediatingTcell-dependent outward vascular remodeling of allogeneic human coronary arteries. FASEB J. 18:606-608
75. Munder M, Mallo M, Eichmann K, Modolell M. 1998. Murine macrophages secrete interferon-γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 187:2103-2108 (Pubitemid 28285581)
76. Gerdes N, Sukhova G, Libby P, Reynolds R, Young J, et al. 2002. Expression of interleukin-18 and functional IL-18 receptor on vascular endothelial cells, smooth muscle cells, and macrophages: implication for atherogenesis. J. Exp. Med. 195:245-257 (Pubitemid 34461268)
77. Hansson G, Jonasson L, Holm J, Clowes M, Clowes A. 1988. Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vivo and in vitro. Circ. Res. 63:712-719 (Pubitemid 18234627)
78. Zhao D,HuY, Miller G, Luster A, Mitchell R, et al. 2002. Differential expression of the IFN-γ-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell α chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J. Immunol. 169:1556-1560 (Pubitemid 34809203)
79. van Loosdregt J, van Oosterhout M, Bruggink A, van Wichen D, van Kuik J, et al. 2006. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 114:1599-1607
80. Suzuki J, Cole S, Batirel S, Kosuge H, Shimizu K, et al. 2003. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am. J. Transpl. 3:968-976 (Pubitemid 36917542)
81. Plutzky J. 2001. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am. J. Cardiol. 88:10K-15K (Pubitemid 33016744)
82. Shimizu K, Mitchell R. 2003. Stem cell origins of intimal cells in graft arterial disease. Curr. Atheroscler. Rep. 5:230-237 (Pubitemid 38898878)
83. Hillebrands J, Klatter F, Rozing J. 2003. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler. Thromb. Vasc. Biol. 23:380-387 (Pubitemid 36337212)
84. Hillebrands J, Klatter F, van den Hurk BM, Popa E, Nieuwenhuis P, et al. 2001. Origin of neointimal endothelium and α-actin-positive smooth muscle cells in transplant arteriosclerosis. J. Clin. Invest. 107:1411-1422 (Pubitemid 32522035)
85. Glaser R, Lu M, Narula N, Epstein J. 2002. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation 106:17-19 (Pubitemid 34747435)
86. Grimm P, Nickerson P, Jeffery J, Savani R, Gough J, et al. 2001. Neointimal and tubulointerstitial infiltration by recipient mesencymal cells in chronic renal-allograft rejection. N. Engl. J. Med. 345:93-97 (Pubitemid 32634567)
87. Simper D, Stalboerger P, Panetta C,Wang S, Caplice N. 2002. Smooth muscle progenitor cells in human blood. Circulation 106:1199-1204 (Pubitemid 34988636)
88. Caplice N, Doyle B. 2005. Vascular progenitor cells: origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem Cells Dev. 14:122-139 (Pubitemid 40677385)
89. Caplice N, Bunch T, Stalboerger P, Wang S, Simper D, et al. 2003. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc. Natl. Acad. Sci. USA 100:4754-4759 (Pubitemid 36457802)
90. Minami E, Laflamme M, Saffitz J, Murry C. 2005. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 112:2951-2958 (Pubitemid 41612297)
91. Hedin U, Roy J, Tran P. 2004. Control of smooth muscle cell proliferation in vascular disease. Curr. Opin. Lipidol. 15:559-565 (Pubitemid 39336584)
92. Fogelstrand P, Osterberg K, Mattsson E. 2005. Reduced neointima in vein grafts following a blockage of cell recruitment from the vein and the surrounding tissue. Cardiovasc. Res. 67:326-332 (Pubitemid 40943626)
93. Sasaki Y, Suehiro S, Becker A, Kinoshita H, Ueda M. 2000. Role of endothelial denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. Heart 83:69-75 (Pubitemid 30307643)
94. Feng S, Lu X, Resendiz J, Kroll M. 2006. Pathological shear stress directly regulates platelet αII βIII signaling. Am. J. Physiol. Cell Physiol. 291:1346-1354
95. Fateh-Moghadam S, Bocksch W, Ruf A, Dickfeld T, Schartl M, et al. 2000. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation 102:890-897 (Pubitemid 30671506)
96. Abele S,Weyand M,Wollin M, Hiemann N, Harig F, et al. 2006. Clopidogrel reduces the development of transplant arteriosclerosis. J. Thorac. Cardiovasc. Surg. 131:1161-1166
97. Weston M, LaBorde O, Yoganathan A. 1999. Estimation of the shear stress on the surface of an aortic valve leaflet. Ann. Biomed. Eng. 27:572-579 (Pubitemid 129585011)
98. Zlotnik A, Yoshie O. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127 (Pubitemid 30398626)
99. Allen S, Crown S, Handel T. 2007. Chemokine:receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 25:787-820
100. Nelson P, Krensky A. 2001. Chemokines, chemokine receptors, and allograft rejection. Immunity 14:377-386 (Pubitemid 32441590)
101. Luster A. 1998. Chemokines: chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436-445
102. von Hundelshausen P, Weber K, Huo Y, Proudfoot A, Nelson P, et al. 2001. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103:1772-1777 (Pubitemid 32291415)
103. Boring L, Gosling J, Chensue S, Kunkel S, Farese R, et al. 1997. Impaired monocyte migration and reduced type-1 (Th1) cytokine responses in CCR2 knockout mice. J. Clin. Invest. 100:2552-2561 (Pubitemid 27514895)
104. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot C, et al. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773-778 (Pubitemid 29152622)
105. Koga S, Auerbach M, Engeman T, Novick A, Toma H, et al. 1999. T cell infiltration into class II MHC- disparate allografts and acute rejection is dependent on the IFN-γ-induced chemokine Mig. J. Immunol. 163:4878-4885 (Pubitemid 29501252)
106. Robinson L, Nataraj C, Thomas D, Howell D, Griffiths R, et al. 2000. A role for fractalkine and its receptor (CX(3)CR1) in cardiac allograft rejection. J. Immunol. 165:6067-6072
107. Gao W, Topham P, King J, Smiley S, Csizmadia V, et al. 2000. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest. 105:35-44 (Pubitemid 30036385)
108. Schecter A, Calderon T, Berman A, McManus C, Fallon J, et al. 2000. Human smooth muscle cells possess functional CCR5. J. Biol. Chem. 275:5466-5471 (Pubitemid 30115180)
109. Goldberg S, van der Meer P, Hesselgesser J, Jaffer S, Kolson D, et al. 2001. CXCR3 expression in human central nervous system diseases. Neuropathol. Appl. Neurobiol. 27:127-138 (Pubitemid 32591969)
110. Sakihama H, Masunaga T, Yamashita K, Hashimoto T, Inobe M, et al. 2004. Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis. Circulation 110:2924-2930 (Pubitemid 39473619)
111. Veillard N, Steffens S, Pelli G, Lu B, Kwak B, et al. 2005. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 112:870-878 (Pubitemid 41170074)
112. Schecter A, Berman A, Taubman M. 2003. Chemokine receptors in vascular smooth muscle. Microcirculation 10:265-272 (Pubitemid 39004254)
113. Kodali R, KimW,Galaria I, Miller C, Schecter A, et al. 2004. CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 24:1211-1216 (Pubitemid 38880010)
114. Shimizu K, Mitchell R. 2003. Chemokine-mediated recruitment of inflammatory and smooth muscle cells in transplant-associated arteriosclerosis. Curr. Opin. Organ Transpl. 8:55-63
115. Mitchell R, Libby P. 2007. Vascular remodeling in transplant vasculopathy. Circ. Res. 100:967-978
116. Denton M, Davis S, Baum M, Melter M, Reinders M, et al. 2000. The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr. Transpl. 4:252-260 (Pubitemid 30799987)
117. Dietrich H, Hu Y, Zou Y, Dirnhofer S, Kleindienst R, et al. 2000. Mouse model of transplant arteriosclerosis: role of intercellular adhesion molecule-1. Arterioscler. Thromb. Vasc. Biol. 20:343-352 (Pubitemid 30086089)
118. Pribila J, Quale A, Mueller K, Shimizu Y. 2004. Integrins and T cell-mediated immunity. Annu. Rev. Immunol. 22:157-180
119. Lacy-Hulbert A, Ueno T, Ito T, Jurewicz M, Izawa A, et al. 2007. β3 integrins regulate lymphocyte migration and cytokine responses in heart transplant rejection. Am. J. Transpl. 7:1080-1090 (Pubitemid 46646786)
120. Moiseeva E. 2001. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc. Res. 52:372-386 (Pubitemid 33153100)
121. Willis A, Pierre-Paul D, Sumpio B, Gahtan V. 2004. Vascular smooth muscle cell migration: current research and clinical implications. Vasc. Endovasc. Surg. 38:11-23 (Pubitemid 38140268)
122. Pure E, Cuff C. 2001. A crucial role for CD44 in inflammation. Trends Mol. Med. 7:213-220
123. Goueffic Y, Guilluy C, Guerin P, Patra P, Pacaud P, et al. 2006. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc. Res. 72:339-348 (Pubitemid 44540201)
124. Jain M, He Q, LeeW-S, Kashiki S, Foster L, et al. 1996. Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. J. Clin. Invest. 97:596-603 (Pubitemid 26057076)
125. Routledge M, Rush D, McKenna R, Gough J, Jeffery J, et al. 1997. The receptor for hyaluronanmediated motility is expressed in human renal allografts and is correlated with Banff chronic rejection scores. Transpl. Proc. 29:2603-2604 (Pubitemid 27382983)
126. Cuff C, Kothapalli D, Azonobi I, Chun S, Zhang Y, et al. 2001. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J. Clin. Invest. 108:1031-1040 (Pubitemid 32946077)
127. Cummins P, von Offenberg-Sweeney N, Killeen M, Birney Y, Redmond E, et al. 2007. Cyclic strain- mediated matrix metralloproteinase regulation within the vascular endothelium: a force to be reckoned with. Am. J. Physiol. Heart Circ. Physiol. 292:H28-42 (Pubitemid 46105162)
128. Glagov S,Weisenberg E, Zarins C, Stankunavicius R, Kolettis G. 1987. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316:1371-1375 (Pubitemid 17079680)
129. Liu J, Sukhova G, Sun J, Xu W, Libby P, et al. 2004. Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:1359-1366
130. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, et al. 2001. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. 89:1111-1121 (Pubitemid 34627868)
131. Laflamme K, Roberge C, Grenier G, Remy-Zolghadri M, Pouliot S, et al. 2006. Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel. FASEB J. 20:E516-24 (Pubitemid 44943886)
132. Wong C, Ganz P, Miller L, Kobashigawa J, Schwarzkopf A, et al. 2001. Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study. J. Heart Lung Transpl. 20:385-392 (Pubitemid 32303142)
133. Schwarzacher S, Uren N, Ward M, Schwarzkopf A, Gianetti N, et al. 2000. Determinants of coronary remodeling in transplant coronary disease: a simultaneous intravascular ultrasound and Doppler flow study. Circulation 101:1384-1389 (Pubitemid 30169859)
134. Eisen H, Tuzcu E, Dorent R, Kobashigawa J, Mancini D, et al. 2003. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349:847-858 (Pubitemid 37025404)
135. Allison A, Eugui E. 2005. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80(Suppl. 2):S181-90 (Pubitemid 41552905)
136. Mannon P, Fuss I, Mayer L, Elson C, Sandborn W, et al. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351:2069-2079 (Pubitemid 39482500)
137. Hommes D, Mikhajlova T, Stoinov S, Stimac D, Vucelic B, et al. 2006. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55:1131-1137 (Pubitemid 44085681)
138. Marx N, Kehrle B, Kohlhammer K, GrubM,KoenigW,et al. 2002.PPARactivators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90:703-710
139. Kosuge H, Haraguchi G, Koga N, Maejima Y, Suzuki J, et al. 2006. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113:2613-2622 (Pubitemid 43948010)
140. Kobashigawa J. 2004. Statins in solid organ transplantation: Is there an immunosuppressive effect? Am. J. Transpl. 4:1013-1018 (Pubitemid 38868589)
141. Behrendt D, Beltrame J, Hikiti H, Wainstein M, Kinlay S, et al. 2006. Impact of coronary endothelial function on the progression of cardiac transplant-associated arteriosclerosis: effect of antioxidant vitamins C and E. J. Heart Lung Transpl. 25:426-433
142. Hayes I, Jordan N, Towers S, Smith G, Paterson J, et al. 1998. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler. Thromb. Vasc. Biol. 18:397-403 (Pubitemid 28125634)
143. Spinetti G, Wang M, Monticone R, Zhang J, Zhao D, et al. 2004. Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler. Thromb. Vasc. Biol. 24:1397-1402 (Pubitemid 39050431)